Revolution Medicines (RVMD) to Release Earnings on Wednesday

Revolution Medicines (NASDAQ:RVMD) is expected to be announcing its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Revolution Medicines to post earnings of ($1.56) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:00 PM ET.

Revolution Medicines Stock Up 4.5%

RVMD stock opened at $100.61 on Wednesday. Revolution Medicines has a twelve month low of $29.17 and a twelve month high of $124.49. The company has a quick ratio of 8.05, a current ratio of 8.05 and a debt-to-equity ratio of 0.16. The stock has a market cap of $19.45 billion, a P/E ratio of -19.46 and a beta of 1.01. The business’s 50-day moving average price is $95.24 and its 200-day moving average price is $67.09.

Wall Street Analyst Weigh In

Several brokerages have weighed in on RVMD. UBS Group raised shares of Revolution Medicines to a “strong-buy” rating in a report on Thursday, December 4th. Mizuho assumed coverage on shares of Revolution Medicines in a research note on Tuesday, October 21st. They set an “outperform” rating and a $90.00 target price on the stock. HC Wainwright increased their price target on Revolution Medicines from $72.00 to $73.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Wedbush reissued an “outperform” rating on shares of Revolution Medicines in a report on Friday, January 9th. Finally, JPMorgan Chase & Co. increased their target price on Revolution Medicines from $71.00 to $82.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Four investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $78.94.

Insider Transactions at Revolution Medicines

In other news, CFO Jack Anders sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $98.00, for a total transaction of $980,000.00. Following the sale, the chief financial officer directly owned 108,065 shares of the company’s stock, valued at $10,590,370. This represents a 8.47% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Margaret A. Horn sold 75,000 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $100.56, for a total transaction of $7,542,000.00. Following the completion of the sale, the chief operating officer owned 141,053 shares of the company’s stock, valued at $14,184,289.68. This trade represents a 34.71% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 173,792 shares of company stock valued at $15,239,440 in the last ninety days. Corporate insiders own 8.20% of the company’s stock.

Institutional Trading of Revolution Medicines

Several hedge funds have recently modified their holdings of RVMD. Nextech Invest Ltd. raised its holdings in shares of Revolution Medicines by 20.7% during the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock worth $332,472,000 after acquiring an additional 1,304,347 shares during the period. Mercer Global Advisors Inc. ADV acquired a new stake in Revolution Medicines during the third quarter worth about $280,000. FORA Capital LLC purchased a new position in Revolution Medicines during the third quarter worth about $297,000. Captrust Financial Advisors raised its stake in Revolution Medicines by 35.9% during the second quarter. Captrust Financial Advisors now owns 11,161 shares of the company’s stock worth $411,000 after purchasing an additional 2,946 shares during the period. Finally, Daiwa Securities Group Inc. boosted its holdings in Revolution Medicines by 89.0% in the 2nd quarter. Daiwa Securities Group Inc. now owns 7,835 shares of the company’s stock valued at $288,000 after purchasing an additional 3,689 shares during the last quarter. 94.34% of the stock is owned by hedge funds and other institutional investors.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.